NK-1 as a melanoma target

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 7, 2011, Pages 889-897

  Muñoz, Miguel ^a   Bernabeu Wittel, José ^a   Coveñas, Rafael ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

apoptosis; metastasis; mitogenesis; neoangiogenesis; NK 1 receptor antagonist; substance P

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTINEOPLASTIC AGENT; APREPITANT; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; G PROTEIN COUPLED RECEPTOR; HISTAMINE; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P; UNCLASSIFIED DRUG; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; HISTAMINE RELEASE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; MELANOMA; METASTASIS; NEUTROPENIA; PANCREAS CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, NEUROKININ-1;

EID: 79958293719     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.586633     Document Type: Review

References (37)

1. Desantis C, Siogel R, Jemal A. Cancer facts and figures 2007 - 2008. American Cancer Society; Atlanta: 2007
2. Munoz M, Rosso M, Covenas R. The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets 2011;12:909-21
3. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 2006;7:1043-52 (Pubitemid 44227587)
4. Munoz M, Rosso M, Robles-Frias MJ, et al. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 2010;90:1259-69
5. Munoz M, Perez A, Rosso M, et al. Antitumoral action of the neurokinin-1 receptor antagonist L-733,060 on human melanoma cell lines. Melanoma Res 2004;14:183-8 (Pubitemid 38879579)
6. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004;112:231-8 (Pubitemid 39244363)
7. Munoz M, Rosso M, Covenas R. The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discov 2006;3:323-9 (Pubitemid 43988115)
8. Munoz M, Rosso M, Aguilar FJ, et al. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 2008;26:111-18
9. Rosso M, Robles-Frias MJ, Covenas R, et al. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 2008;29:245-54
10. Munoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 2010;28:187-93
11. Munoz M, Rosso M, Gonzalez-Ortega A, et al. The NK-1 receptor antagonist L- 732,138 induces apoptosis and counteracts substance P-related mitogenesis in human melanoma cell lines. Cancers 2010;2:611-23
12. Esteban F, Munoz M, Gonzalez-Moles MA, et al. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metast Rev 2006;25:137-45 (Pubitemid 43723988)
13. Munoz M, Rosso M, Perez A, et al. Antitumoural action of the neurokinin-1- receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005;46:2567-70 (Pubitemid 43119507)
14. Munoz M, Rosso M, Covenas R, et al. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 2007;48:2775-81 (Pubitemid 351261233)
15. Munoz M, Gonzalez-Ortega A, Covenas R. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK- 1 receptor antagonists on acute lymphoblastic leukemia cell lines. Invest New Drugs 2011;In press
16. Munoz M, Rosso M, Covenas R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 2010;17:504-16
17. Mochizuki-Oda N, Nakajima Y, Nakanishi S, et al. Characterization of the SP receptor-mediated Ca influx in cDNA transfected CHO cells. J Biol Chem 1994;269:9651-8
18. Garcia M, Sakamoto K, Shigekawa M, et al. Multiple mechanisms of arachidonic acid release in Chinese hamster ovary cells transfected with cDNA of SP receptor. Biochem Pharmacol 1994;48:1735-41 (Pubitemid 24338999)
19. Seabrook GR, Fong TM. Thapsigargin blocks the mobilization of intracellular Ca caused by activation of human NK1 (long) receptors expressed in CHO cells. Neurosci Lett 1993;152:9-12 (Pubitemid 23149300)
20. Takeda Y, Blount P, Sachais BS, et al. Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in CHO cells and evidence for differential stimulation of inositol 1, 4, 5-triphosphate and camp second messenger responses. J Neurochem 1992;59:740-5
21. Nakajima Y, Tsuchida K, Negishi M, et al. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cAMP cascades in transfected Chinese hamster ovary cells. J Biol Chem 1992;267:2437-42
22. Mitsuhashi M, Ohashi Y, Schichijo S, et al. Multiple intracellular signalling pathways of the neuropeptide SP receptor. J Neurosci Res 1992;32:437-43
23. Munoz M, Perez A, Covenas R, et al. Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol 2004;142:105-12 (Pubitemid 38691234)
24. Munoz M, Rosso M, Perez A, et al. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005;39:427-32 (Pubitemid 41073623)
25. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 1996;56:4983-91 (Pubitemid 26374439)
26. Bigioni M, Benzo A, Irrissuto C, et al. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 2005;16:1083-9 (Pubitemid 41565774)
27. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,DTrp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 2005;65:2738-45 (Pubitemid 40490075)
28. Shi J, Zheng D, Liu Y, et al. Over-expression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005;65:1687-92 (Pubitemid 40478593)
29. Paul B, Trovato JA, Thompson J, et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010;16:45-51
30. Choi MR, Jiles C, Seibel NL. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). J Pediatr Hematol Oncol 2010;32:e268-71
31. Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010;5:e10968
32. Roila F, Rolski J, Ramlau R, et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol 2009;20:1867-73
33. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008;181:879-84 (Pubitemid 351846821)
34. Exadaktylos AK, Buggy DJ, Moriarty DC, et al. Can anesthetics technique for primary breast cancer surgery affect recurrence of metastases? Anesthesiology 2006;105:660-4 (Pubitemid 44477309)
35. Munoz M, Rosso M, Casinello F, et al. Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res Treat 2010;122:601-3
36. Kitchens CA, McDonald PR, Pollack IF, et al. Synergy between microtubule-destabilizing agents and neurokinin 1 receptor antagonists identified by an siRNA synthetic lethal screen. FASEB J 2009;23:756.13
37. Alfieri AB, Cubeddu LX. Efectos de los antagonistas de los receptores NK1 y de la dexametasona sobre la inflamacion neurogenica inducida por ciclofosfamida y por radiacion X, en la rata. AVFT 2004;23:61-6